Bedrijfsoverzicht
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical entity dedicated to the development and commercialization of therapeutic candidates specifically targeting eye care conditions within the United States market. The company operates within the broader healthcare sector, focusing on the specialized biotechnology industry, which implies a high level of research intensity and regulatory scrutiny regarding product safety and efficacy. With a total market capitalization of $3.09 billion, an annual revenue of $451.36 million, and a workforce comprising 370 employees, the firm presents itself as a significant player in its niche. These valuation and revenue figures indicate that the market assigns substantial value to the company's pipeline and current commercial operations, suggesting a robust position relative to typical early-stage biotechnology peers, even as the company navigates the challenges of scaling therapeutic candidates like XDEMVY for demodex blepharitis.
Financiële gezondheid
The company reported revenue of $451.36 million over the trailing twelve months, yet it recorded a net income of -$66,418,000 and an EBITDA of -$69,153,000. This significant gap between positive revenue and substantial negative net income reveals a cost structure where operating expenses, likely driven by research, development, and commercialization activities, far exceed the gross profits generated by sales. The free cash flow stands at -$164,000, which indicates that while the company has managed to generate minimal net cash outflows recently, it remains in a cash-burning phase typical for commercial-stage biotech firms investing heavily in growth. Analyzing the margins, the company boasts a gross margin of 79.0%, reflecting high pricing power or low cost of goods sold relative to revenue, while the operating margin sits at -5.3% and the profit margin is -14.7%, highlighting that overhead and R&D costs are consuming a large portion of the gross revenue. Regarding liquidity and leverage, the company holds $417.27 million in cash against $83.04 million in debt, resulting in a debt-to-equity ratio of 24.18, which suggests a highly leveraged balance sheet structure relative to equity but is mitigated by the substantial cash reserve. The current ratio of 3.85 indicates a strong short-term liquidity position, meaning the company possesses ample current assets to cover its short-term liabilities without immediate distress. Furthermore, the return on equity is -23.4% and the return on assets is -9.4%, metrics that reveal that management has not yet generated positive returns on the capital invested, a common characteristic of companies prioritizing reinvestment and expansion over immediate profitability.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to the net loss, whereas the forward P/E is 25.12. The absence of a trailing P/E while a forward P/E exists implies that the market is pricing in a future trajectory where earnings are expected to turn positive, though the specific timeline for profitability is not detailed in current metrics. The price-to-book ratio stands at 8.99, indicating that the stock trades at a significant premium over its book value, which is typical for biotechnology companies where intellectual property and pipeline potential are valued higher than tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 6.84 and an EV/EBITDA of -39.82 provide further context, suggesting the market values the company based on revenue generation potential rather than current earnings power, as negative EV/EBITDA confirms the lack of current operational profitability. In terms of price action, the stock has reached a 52-week high of $85.25 and a 52-week low of $38.51. Without a specific current price provided in the available facts to calculate a precise percentage, the trading range establishes the volatility bounds within which the asset has moved over the past year, defining the historical ceiling and floor for risk assessment. The beta value is 0.63, which indicates that the stock's price volatility is lower than that of the broader market, suggesting a defensive characteristic or lower correlation with general market swings compared to high-beta equities.
Growth & Income
Revenue growth year-over-year is 128.4%, demonstrating a rapid expansion in sales, while earnings growth is N/A due to the company's current loss-making status. The disparity between high revenue growth and non-existent earnings growth implies that top-line expansion is occurring, but profitability has not yet been achieved to translate that revenue into net income. As a non-dividend payer, the company does not distribute a dividend yield or has a payout ratio of 0.0%, meaning it reinvests all earnings—or rather, all available cash—back into the business to fuel further development and commercialization efforts rather than paying shareholders. The overall growth and income profile is characterized by aggressive top-line expansion supported by a cash-rich balance sheet, though the income profile remains negative until the company transitions to profitability.